AJ Lanigan: Sure. In truth, pharma corporations are earning big dollars with treatment options like Keytruda and Opdivo that deal with PD-1 and PD-L1. Right here’s the super amazing section: imagine checkpoints as targeted visitors indicators. You don’t want an immune method that’s operating wild like a freight train around a cliff.Ryan Stern